Clinical Trials Logo

Adenocarcinoma of the Pancreas clinical trials

View clinical trials related to Adenocarcinoma of the Pancreas.

Filter by:

NCT ID: NCT03717298 Completed - Pancreatic Cancer Clinical Trials

Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

The investigators hypothesized that with the administration of the nutritional supplement Ocoxin-Viusid® is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients diagnosed with advanced pancreatic adenocarcinoma, treated at the "Hermanos Ameijeiras" Surgical Clinical Hospital. Phase II clinical trial, open, multicenter, nonrandomized.

NCT ID: NCT03490760 Terminated - Clinical trials for Adenocarcinoma of the Pancreas

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

Start date: November 9, 2018
Phase: Phase 2
Study type: Interventional

This is a single-institution, single-arm phase II trial of Durvalumab combined with Radiation Therapy (RT) for metastatic pancreatic cancer patients who have progressed through first-line chemotherapy.

NCT ID: NCT03221400 Recruiting - Gastric Cancer Clinical Trials

PEN-866 in Patients With Advanced Solid Malignancies

Start date: August 29, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

NCT ID: NCT03065985 Withdrawn - Clinical trials for Adenocarcinoma of the Pancreas

EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma.

Start date: August 2017
Phase: Phase 2
Study type: Interventional

This study will assess if endoscopic ultrasound radiofrequency application in patients with inoperable pancreatic cancer and chemotherapy confers survival benefit when compared to patients receiving best medical care and chemotherapy .

NCT ID: NCT02707328 Terminated - Pancreatic Cancer Clinical Trials

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Start date: January 2015
Phase: Phase 1
Study type: Interventional

This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.

NCT ID: NCT02707315 Recruiting - Pancreatic Cancer Clinical Trials

A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer

Start date: January 2013
Phase: Phase 0
Study type: Interventional

This study is evaluating stereotactic radiosurgery (CyberKnife) plus chemotherapy for the treatment of potentially resectable adenocarcinoma of the pancreas

NCT ID: NCT02564146 Completed - Clinical trials for Metastatic Pancreatic Cancer

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine

ALPACA
Start date: December 2016
Phase: Phase 2
Study type: Interventional

ALPACA is an interventional, multicentre, open-label, randomized active-controlled phase II trial with two arms. To estimate the treatment effect on overall survival, feasibility, efficacy and safety of alternating treatment cycles of gemcitabine monotherapy followed by nab-paclitaxel/gemcitabine relative to standard continuing nab-paclitaxel/gemcitabine cycles in first-line treatment for metastatic pancreatic cancer in patients having received 3 cycles of induction therapy with standard nab-paclitaxel/gemcitabine.

NCT ID: NCT02037230 Completed - Clinical trials for Adenocarcinoma of the Pancreas

Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

Start date: January 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The investigators' long-term goal is to improve the survival of patients with pancreatic cancer by enhancing the efficacy of gemcitabine-radiation by adding the Wee1 inhibitor MK-1775.

NCT ID: NCT02030860 Completed - Clinical trials for Adenocarcinoma of the Pancreas

A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Start date: January 2014
Phase: Phase 1
Study type: Interventional

This study is a randomized pilot/pharmacodynamic/genomic study of neoadjuvant paricalcitol to target the microenvironment in resectable pancreatic cancer to determine the effect of targeting the vitamin D metabolic program in the tumors of patients treated with one cycle of gemcitabine/abraxane with or without paricalcitol prior to surgery for resectable pancreatic cancer through an assessment of cellular and imaging markers.

NCT ID: NCT01497392 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

Start date: March 29, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of dovitinib lactate when given together with gemcitabine hydrochloride and capecitabine in treating patients with advanced or metastatic solid tumors or advanced pancreatic cancer. Dovitinib lactate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving dovitinib lactate together with combination chemotherapy may kill more tumor cells